Novel Drug Delivery Systems | Pharmaceutics | GPAT Mock Test

1. What is the most commonly used supercritical fluid in pharmaceutical processing due to its non-toxic nature and mild critical conditions (31.1°C and 73.8 bar)?

2. Which of the following acts as the primary rate-limiting barrier for drug permeation in transdermal drug delivery systems?

3. The Higuchi model is most commonly used to describe drug release from which type of controlled release system?

4. Liposomes are vesicular systems in which one or more concentric lipid bilayers enclose:

5. The “Enhanced Permeability and Retention (EPR) effect” is a key mechanism associated with:

6. Chlorofluorocarbons (CFCs) were phased out as propellants in metered-dose inhalers (MDIs) primarily due to their adverse effect on:

7. Which inhalation device delivers a drug as a fine aerosolized mist and does not require patient coordination of actuation and inhalation, making it suitable for children and the elderly?

8. Multiple emulsions of the W/O/W type are primarily developed for which of the following purposes?

9. The polymer Eudragit® L100 is used for enteric coating because it contains carboxylic acid groups and dissolves at:

10. Which of the following is a widely known example of a chemical penetration enhancer used in transdermal formulations?

11. Solid Lipid Nanoparticles (SLNs) are colloidal carriers composed of a solid lipid core which is stabilized by:

12. Attaching a ligand like transferrin or folic acid to the surface of a nanoparticle to bind to specific receptors on cancer cells is an example of:

13. The RESS (Rapid Expansion of Supercritical Solutions) process in supercritical fluid technology is used for:

14. In a reservoir-type controlled release system, the drug release rate is primarily governed by:

15. In a metered-dose inhaler (MDI), what is the function of the actuator?

16. Comirnaty® (Pfizer-BioNTech COVID-19 vaccine) utilizes which novel drug delivery system to protect and deliver its fragile mRNA component?

17. Niosomes are vesicular drug delivery systems that are structurally similar to liposomes but are composed of:

18. Iontophoresis enhances transdermal drug delivery by using:

19. A controlled release system that delivers a drug at a constant rate (e.g., mg/hour) over a prolonged period is said to follow:

20. A key formulation challenge in maintaining the stability of multiple emulsions (e.g., W/O/W) is preventing:

21. For effective deposition in the deep lung (alveolar region), the ideal mass median aerodynamic diameter (MMAD) of particles in an inhalation system is:

22. Monoclonal antibodies (mAbs), used in products like Herceptin®, are a classic example of biomolecules used for:

23. Osmotic pumps, like the OROS® (Oral Release Osmotic System) technology, release drugs at a controlled rate based on the principle of:

24. The process of coating nanoparticles with polyethylene glycol (PEG), known as PEGylation, serves primarily to:

25. A transdermal patch in which the drug is uniformly dispersed within a polymer matrix, and this matrix controls the drug release, is known as a: